1. A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY. (21st February 2022) Authors: Panaccione, R; Danese, S; Zhouwen, W; Pangan, A; Hébuterne, X; Nakase, H; D'Haens, G; Panes, J; Lindsay, J; Higgins, P; Loftus, E; Sandborn, W; Xie, W; Sanchez gonzalez, Y; Liu, J; Weinreich, M; Vermeire, S Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 5(2022)Supplement 1 Page Start: 18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A15 EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY. (4th March 2021) Authors: Feagan, B G; Loftus, E V; Danese, S; Vermeire, S; Sandborn, W J; Ritter, T; Mehta, R; Seidler, U; Seibold, F; Beales, I; Kim, H; McNally, J; Yun, C; Zhao, S; Liu, X; Tasset, C; Besuyen, R; Watanabe, M; Schreiber, S; Rogler, G Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 4(2021)Supplement 1 Page Start: 18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A17 EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY. (4th March 2021) Authors: Peyrin-Biroulet, L; Loftus, E V; Danese, S; Vermeire, S; Sandborn, W J; Fogel, R; Nijhawan, S; Kempinski, R; Filip, R; Hospodarskyy, I; McNally, J; Yun, C; Zhao, S; Liu, X; Tasset, C; Besuyen, R; Watanabe, M; Schreiber, S; Rogler, G; Hibi, T Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 4(2021)Supplement 1 Page Start: 21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A184 EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL. (7th March 2023) Authors: Danese, S; Dignass, A; Matsuoka, K; Ferrante, M; Long, M; Redondo, I; Gibble, T H; Moses, R; Morris, N; Li, X; Milch, C; Abreu, M; Jones, J Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 6(2023)Supplement 1 Page Start: 28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A185 SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL. (7th March 2023) Authors: Dignass, A; Danese, S; Matsuoka, K; Ferrante, M; Long, M; Redondo, I; Gibble, T H; Moses, R; Li, X; Morris, N; Milch, C; Abreu, M; Jones, J Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 6(2023)Supplement 1 Page Start: 29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Issue 10 (11th September 2003) Authors: Danese, S; Katz, J A; Saibeni, S; Papa, A; Gasbarrini, A; Vecchi, M; Fiocchi, C Journal: Gut Issue: Volume 52:Issue 10(2003) Page Start: 1435 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. AODWE-008 Multicentre ecco collaborative group study to evaluate the need for re-intervention following multimodal treatment in crohn`s disease with perianal fistula. (17th June 2017) Authors: Black, C; Pugliese, D; Sahnan, K; Hart, A; Fiorino, G; Armuzzi, A; Katsanos, K; Christodoulou, D; Selinger, C; Maconi, G; Kopylov, U; Bosca-Watts, M; Karmiris, K; Davidov, Y; P, P Ellul; Whitehead, E; Ben-Horin, S; Danese, S; Fearnhead, N; Sebastian, S Journal: Gut Issue: Volume 66(2017)Supplement 2 Page Start: A124 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in different populations. Issue 8 (15th July 2003) Authors: Papa, A; Danese, S; Armuzzi, A; Gaetani, E; Flex, A; Pola, P; Gasbarrini, A Journal: Gut Issue: Volume 52:Issue 8(2003) Page Start: 1227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Author response to: Covid-19-related pancreatic injury. Issue 7 (30th April 2020) Authors: Spinelli, A; Pellino, G; Danese, S Journal: British journal of surgery Issue: Volume 107:Issue 7(2020) Page Start: e191 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. CD40 antisense based strategy for inflammatory bowel disease: shutting down multiple cellular communication systems. Issue 6 (11th May 2005) Authors: Danese, S; Sans, M; Gasbarrini, A Journal: Gut Issue: Volume 54:Issue 6(2005) Page Start: 891 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗